Table 1.

MDS/sAML Patients with C-CBL Mutations.

Patient No.	Age (Year)/Sex	WHO Subtype	Marrow Blasts (%)	Cytogenetics at MDS	C-CBL Amino Acid Change		IPSS	Time to AML (Months)	Survival from MDS (Months)
			MDS/sAML		MDS	sAML
001	70/F	RAEB-1/sAML	5.5/71.7	NA	-	Y371S	>1.0	3.5	3.9
010	48/F	RAEB-2/sAML	17.0/32.2	46,XX,dup(1)(q21q32)[28/28]	-	F418S	2.5	5.3	28.1
032	72/M	RAEB-2/sAML	16.6/79.0	46,XY,-5,-8,-9,add(11)(q25), t(12;18)(p11;p11),-17,+4mar[6/20]	-	L370_Y371 ins L	3.0	2.2	3.3
109	22/M	RCMD/sAML	1.4/35.2	NA	-	L399V	≥0.5	7.0	7.6
119	54/F	RCMD/sAML	5.0/59.0	NA	G415S	G415S	1.0	22.3	25.2
125	64/F	RAEB-1/sAML	8.5/45.8	45,XX,-7[22/26]/46,XX[4/26]	-	C416W	1.5	14.9	23.8+

F indicates female; M, male; NA, not available; WHO, World Health Organization.